Drugs for Triple X Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 164)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ethanol |
Approved |
Phase 4 |
|
64-17-5 |
702 |
Synonyms:
(C6-C9)Alkyl alcohol
[CH2Me(OH)]
[OEtH]
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
1-Hydroxyethane
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
absolute alcohol
Absolute alcohol
Absolute Alcohol
Absolute ethanol
Absolute Ethanol
Absolute ethyl alcohol
AC1L19TW
AC1Q31MM
Aethanol
Aethanol [German]
Aethylalkohol
AHD 2000
AI3-01706
Alcare hand degermer
Alcare Hand Degermer
alcohol
Alcohol
Alcohol (ethyl)
Alcohol (USP)
Alcohol [USP]
ALCOHOL 5% IN D5-W
Alcohol anhydrous
Alcohol Anhydrous
Alcohol dehydrated
Alcohol denatured
alcohol etilico
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Absolute
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, Dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, Diluted
Alcohol, ethyl
Alcohol, grain
Alcohol, Grain
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool ethylique
Alcool Ethylique
Alcool éthylique
Alcool etilico
Alcool Etilico
Algrain
Alkohol
Alkohol [German]
Alkoholu etylowego
Alkoholu Etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
bmse000297
C00469
C2H5OH
C2H6O
Caswell No. 426
Caswell No. 430
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
|
CHEMBL545
CID702
Colamine
Cologne spirit
Cologne Spirit
Cologne spirits
D000431
D00068
DB00898
Dehydrated alcohol
Dehydrated ethanol
Dehydrated Ethanol
Denatured alcohol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Denatured Ethanol
Desinfektol el
Desinfektol EL
Diluted alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
Envision Conditioner Pdd 9020
EOH
EOX
Esumiru WK 88
ETA
etanol
Etanol
Etanolo
Etanolo [Italian]
ethanol
éthanol
Ethanol (9CI)
Ethanol [JAN]
Ethanol 200 proof
Ethanol 200 Proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol Vapor
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl alc
ethyl alcohol
Ethyl alcohol
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl Alcohol Anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl Hydrate
Ethyl hydroxide
Ethyl Hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
EtOH
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
grain alcohol
Grain alcohol
Hinetoless
HSDB 531
HSDB 82
Hydroxyethane
HYDROXYETHYL GROUP
I14-12648
IMS 99
Infinity pure
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated spirit
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
MolPort-001-785-844
NCGC00091458-01
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spirits OF wine
spiritus vini
Spiritus vini
Spirt
SY Fresh M
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
UNII-3K9958V90M
USAF EK-1597
WLN: Q2
|
|
2 |
|
Labetalol |
Approved |
Phase 4 |
|
36894-69-6 |
3869 |
Synonyms:
2-Hydroxy-5-(1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)benzamide
2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide
2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide
36894-69-6
3-Carboxamido-4-hydroxy-a-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
3-Carboxamido-4-hydroxy-α-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
AB00053659
AC-18747
AC1L1GW8
AH 5158
AH-5158
Albetol
Alphapharm brand OF labetalol hydrochloride
Apo labetalol
Apo-labetalol
ApoLabetalol
Apotex brand OF labetalol hydrochloride
BPBio1_000170
BRD-A07440155-003-05-6
BSPBio_000154
BSPBio_003142
C07063
Celltech brand OF labetalol hydrochloride
CHEBI:6343
CHEMBL429
CID3869
D08106
DB00598
Dilevalol
DivK1c_000474
EINECS 253-258-3
Faro brand OF labetalol hydrochloride
Glaxo wellcome brand OF labetalol hydrochloride
GlaxoSmithKline brand OF labetalol hydrochloride
HSDB 6537
Hydrochloride, labetalol
Ibidomide
IDI1_000474
Kabetalol
KBio1_000474
KBio2_002087
KBio2_004655
KBio2_007223
KBio3_002642
|
KBioGR_000727
KBioSS_002087
Kern brand OF labetalol hydrochloride
L001344
labetalol
Labetalol
Labétalol
Labetalol (INN)
Labetalol [INN:BAN]
Labetalol hydrochloride
Labetalol, (R,R)-isomer
Labetalolum
Labetalolum [INN-Latin]
Labetolol
Leiras brand OF labetalol hydrochloride
Lopac0_000687
LS-26936
MolPort-003-898-140
NCGC00015595-06
NCGC00089800-02
NINDS_000474
Normodyne
NORMOZIDE
Presolol
Prestwick0_000277
Prestwick1_000277
Prestwick2_000277
Prestwick3_000277
R,R Labetalol
R,R-Labetalol
SBB067266
Sch-19927
Schering brand OF labetalol hydrochloride
Shire brand OF labetalol hydrochloride
Sigma brand OF labetalol hydrochloride
SPBio_000905
SPBio_002373
Spectrum_001607
Spectrum2_000863
Spectrum3_001581
Spectrum4_000184
Spectrum5_001010
TL8002725
Trandate
UNII-R5H8897N95
|
|
3 |
|
Nitroglycerin |
Approved, Investigational |
Phase 4 |
|
55-63-0 |
4510 |
Synonyms:
1,2,3-propanetrioltrinitrate
1,2,3-Propanetrioltrinitrate
1,2,3-Propanetrioltrinitric acid
1,2,3-propanetriyl nitrate
1,2,3-Propanetriyl nitrate
1,2,3-Propanetriyl nitric acid
100292-13-5
105469-31-6
55-63-0
80066-48-4
8013-23-8
9010-02-0
AC1L1IBV
Adesitrin
Aldonitrin
Angibid
Anginine
Angiolingual
Angiplex
Anglix
Angonist
Angorin
Anogesic
Aquo-Trimitrosan
BIDD:GT0142
Blasting gelatin
Blasting oil
BRN 1802063
Buccal
Buccard
c0061
C07455
C3H5N3O9
Cardabid
Cardamist
Cardinit
Cardiodisco
CCRIS 4089
Cellegesic
CHEBI:28787
CHEMBL730
Chitamite
CID4510
Colenitral
Cordipatch
Corditrine
Coro-Nitro
CPD-143
D00515
D005996
Dauxona
DB00727
Deponit
Deponit 5
Deponit TTS 10
Deponit TTS 5
Deponit-5
Diafusor
Discotrine
Dynamite
EINECS 200-240-8
Epinitril
Gepan Nitroglicerin
Gilucor nitro
Gilustenon
Glonoin
Glycerin trinitrate
Glycerin trinitric acid
Glycerine trinitrate
Glycerintrinitrate
Glycerol trinitrate
Glycerol trinitric acid
Glycerol, nitrate triester
Glycerol, nitric acid triester
Glyceroli trinitratis
Glyceroltrinitraat
Glyceroltrinitrat
Glyceryl
Glyceryl nitrate
Glyceryl trinitrate
Glyceryl trinitric acid
Glycerylnitrat
Glytrin
GTN
GTN-Pohl
Herwicard
Herzer
HMS2094M15
HSDB 30
IMX-150
Klavikordal
Lenitral
Lentonitrina
LS-7741
MED-2002
Millisrol
Minitram
Minitran
Minitran (TN)
Minitro
Mionitrat
Mi-Trates
MQX-503
Myocon
Myoglycerin
Myovin
Natispray
Neos nitro OPT
NG
Niglin
Niglycon
Niong
Niong Retard
Nirmin
Nitora
Nitradisc
Nitradisc Pad
Nitradisc TTS
Nitrangin
Nitrek
Nit-Ret
Nitriderm
Nitriderm TTS
Nitrine-TDC
Nitro bid
Nitro Bid
Nitro dur
Nitro Dur
Nitro Dur TTS
NITRO IV
Nitro Mack Retard
Nitro Retard
Nitro Rorer
Nitroard
Nitrobaat
Nitro-bid
NitroBid
Nitro-Bid
Nitro-bid (TN)
Nitrobid Oint
Nitrobukal
Nitrocap
NitrocapT.D
NitrocapT.D.
Nitrocard
Nitrocerin
Nitrocine
Nitrocine 5
|
Nitroclyn
Nitrocontin
Nitrocontin Continus
NitroCor
Nitrocot
Nitroderm
Nitroderm TTS
Nitroderm TTS Ext
Nitroderm TTS-5
Nitrodisc
Nitro-dur
NitroDur
Nitro-dur (TN)
Nitro-Dur 10
Nitro-Dur 5
Nitrodyl
Nitrodyl TTS
Nitrogard
Nitrogard-SR
Nitro-Gesanit Retard
Nitroglicerina
Nitrogliceryna
Nitroglin
nitroglycerin
Nitroglycerin
Nitroglycerin (NG)
Nitroglycerin ointment
Nitroglycerin-ACC
Nitroglycerine
Nitroglycerol
Nitroglyn
Nitroject
Nitrol
Nitrol Ointment
Nitrolan
Nitro-lent
Nitroletten
Nitrolin
Nitrolingual
Nitrolingual Spray
Nitrolowe
Nitromack Retard
Nitro-Mack Retard
Nitro-M-Bid
Nitromed
Nitromel
Nitromex
Nitromint
Nitromint Aerosol
Nitromint Retard
Nitromist
NitroMist
Nitromist (TN)
Nitronal Aqueous
Nitronet
Nitrong
Nitrong parenteral
Nitrong Retard
Nitrong-SR
Nitro-Par
Nitropatch
Nitropen
Nitropercuten
Nitroperlinit
Nitro-Pflaster
Nitroplast
Nitroprol
Nitropront
Nitroprontan
NitroQuick
NitroQuik
Nitrorectal
Nitroretard
Nitrorex
Nitrospan
Nitro-Span
Nitrostabilin
Nitrostat
Nitro-Time
Nitrovis
Nitrozell retard
NK-843
NTG
Nysconitrine
Percutol
Percutol Oint
Percutol Oint.
Perganit
Perglottal
Perlinganit
Plastranit
Polnitrin
Propane-1,2,3-triyl trinitrate
Propane-1,2,3-triyl trinitric acid
Ratiopharm
RCRA waste no. P081
Rectogesic
SDM No. 17
SK-106N
SK-866
SK-878
Soup
Spirit of glonoin
Susadrin
Suscard
Sustac
Sustak
Sustonit
Temponitrin
TNG
Top-Nitro
Transderm nitro
Transderm Nitro
Transderm-N TTS
Transderm-nitro
Transderm-nitro (TN)
Transderm-Nitro TTS
Transiderm-nitro
Tridil
Tridil sublin
Trinalgon
Trinipatch
Triniplas
Trinitrate, glyceryl
Trinitrate, Glyceryl
Trinitrin
Trinitrin Tablets
Trinitrina Erba
Trinitrine
Trinitroglycerin
Trinitroglycerol
Trinitrol
Trinitrolong
Trinitron
Trinitrosan
Turicard
UN0143
UN0144
UN1204
UN3064
UN3319
UNII-G59M7S0WS3
Vascana
Vasoglyn
Vasolator
Vernies
Willong
|
|
4 |
|
Cetuximab |
Approved |
Phase 4 |
|
205923-56-4 |
56842117 2333 |
Synonyms:
205923-56-4
Anti EGFR
cetuximab
Cetuximab
Cétuximab
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
|
Cetuximab (USAN/INN)
Cetuximabum
D03455
Erbitux
Erbitux (TN)
IMC-C225
|
|
5 |
|
Fluorouracil |
Approved |
Phase 4 |
|
51-21-8 |
3385 |
Synonyms:
1004-03-1
1-fluoro-1h-pyrimidine-2,4-dione
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 Fluorouracil
5 Fluorouracil biosyn
5 FU lederle
5 FU Lederle
5 FU medac
5 HU hexal
5 HU Hexal
51-21-8
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-fluoropyrimidine-2,4(1H,3H)-dione
5-Fluoropyrimidine-2,4-dione
5-fluorouracil
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5FU
5-FU
5-FU (TN)
5-FU lederle
5-FU Lederle
5-FU medac
5-HU hexal
5-HU Hexal
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
AI3-25297
AKOS000119162
AKOS003237897
Allergan brand OF fluorouracil
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
biosyn Brand of Fluorouracil
Biosyn brand OF fluorouracil
BSPBio_002048
C07649
C4H3FN2O2
Carac
Carac (TN)
Carzonal
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
Cinco FU
CPD000038082
CPD0-1327
CSP Brand of Fluorouracil
CSP Brand OF fluorouracil
Cytosafe
D005472
D00584
Dakota brand OF fluorouracil
Dakota Brand of Fluorouracil
Dakota, fluorouracile
Dakota, Fluorouracile
DB00544
Dermatech brand OF fluorouracil
Dermatech Brand of Fluorouracil
Dermik brand OF fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
EINECS 200-085-6
EU-0100536
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
Ferrer brand OF fluorouracil
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro uracile icn
Fluoro Uracile ICN
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
fluorouracil
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil [USAN:INN:BAN:JAN]
Fluorouracil gry
Fluorouracil GRY
Fluorouracil mononitrate
Fluorouracil Mononitrate
Fluorouracil monopotassium salt
Fluorouracil Monopotassium Salt
Fluorouracil monosodium salt
Fluorouracil Monosodium Salt
Fluorouracil potassium salt
Fluorouracil Potassium Salt
Fluorouracil teva brand
Fluorouracil Teva Brand
Fluorouracile
Fluoro-uracile
|
Fluorouracile [DCIT]
Fluorouracile dakota
Fluorouracile Dakota
Fluoro-uracile icn
Fluoro-Uracile ICN
Fluorouracil-gry
Fluorouracil-GRY
Fluorouracilo
Fluoro-uracilo
Fluorouracilo [INN-Spanish]
Fluorouracilo ferrer far
Fluorouracilo Ferrer Far
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
FT-0082524
Ftoruracil
FU
Gry brand OF fluorouracil
Gry Brand of Fluorouracil
Haemato brand OF fluorouracil
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
Hexal Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
I07-0022
ICN brand OF fluorouracil
ICN Brand of Fluorouracil
IDI1_000054
IN1335
inhibits thymilidate synthetase
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
Lopac0_000536
Lopac-F-6627
LS-153
medac Brand of Fluorouracil
Medac brand OF fluorouracil
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
nchembio.90-comp3
nchembio809-comp6
NCI60_001652
Neocorp brand OF fluorouracil
Neocorp Brand of Fluorouracil
Neofluor
NINDS_000054
NSC 19893
NSC19893
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Onkoworks Brand of Fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
ribosepharm Brand of Fluorouracil
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche brand OF fluorouracil
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
Spectrum_000841
SPECTRUM1500305
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
STK297802
T5233394
tetratogen
Teva brand OF fluorouracil
Teva Brand of Fluorouracil
Timazin
TL8006093
U 8953
U-8953
Ulup
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
WLN: T6MVMVJ EF
ZINC00897110
|
|
6 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
7 |
|
Vitamin D3 |
Approved, Nutraceutical |
Phase 4 |
|
67-97-0 |
6221 5280795 |
Synonyms:
()-Vitamin D3
(+)-vitamin D3
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
47763_SUPELCO
57651-82-8
67-97-0
7-DEHYDROCHOLESTEROL
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
ACTIVATED
Activated 7-dehydrocholesterol
Arachitol
Bio-0845
bmse000507
BPBio1_000460
BSPBio_000418
BSPBio_002408
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
Calciol
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
cholecalciferol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferols
Cholecalciferolum
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
|
CID7067440
CID7251172
CID7251174
CID9821465
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Dihydrocholesterol
DivK1c_006276
Duphafral D3 1000
Ebivit
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
FeraCol
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC375571
NSC-375571
Oleovitamin D3
Prestwick_63
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Provitamine
Provitina
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SpecPlus_000180
Spectrum_001163
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
SR-05000001559
SR-05000001559-3
ST057172
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
Vi-de-3-hydrosol
Vigorsan
VITAMIN D
Vitamin D 3
vitamin d-3
Vitamin D3
Vitamin D-3
Vitamin D3 emulsifiable
VITAMIN D3 POWDER
VITAMIN_D3
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
δ-D
|
|
8 |
|
Calcifediol |
Approved, Nutraceutical |
Phase 4 |
|
19356-17-3 |
6433735 5283731 |
Synonyms:
(1R,3Z)-3-[(2E)-2-[(1R,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol
(3S,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-3,25-diol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol
(3S,5Z,7E)-9,10-Secocholesta-5,7,10-triene-3,25-diol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol
(5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol
17938_FLUKA
17938_SIGMA
19356-17-3
25 Hydroxycholecalciferol
25 Hydroxycholecalciferol monohydrate
25 Hydroxyvitamin D 3
25 Hydroxyvitamin D3
25(OH)D3
25-(OH)Vitamin D3
25631-40-7
25-hydroxycholecalciferol
25-Hydroxycholecalciferol
25-Hydroxy-cholecalciferol
25-Hydroxycholecalciferol (Calcifediol)
25-Hydroxycholecalciferol monohydrate
25-Hydroxycholescalciferol
25-Hydroxyvitamin D
25-Hydroxyvitamin D 3
25-hydroxyvitamin D3
25-Hydroxyvitamin D3
25-Hydroxyvitamin D3 monohydrate
3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol
3-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANOL
5,6-cis-25-Hydroxyvitamin D3
5,6-trans-25-Hydroxycholescalciferol
5,6-trans-9,10-Seco-5,7,10(19)-cholestatrien-3beta,25-diol
9,10-Secocholesta-5,7,10(19)-triene-3b,25-diol
9,10-Secocholesta-5,7,10(19)-triene-3beta,25-diol
AC1NR2WF
AC1O5GOQ
Anhydrous, calcifediol
Aventis brand OF calcifediol
B91135EC-8937-4D8B-A533-CCD82F33C1B0
BML2-E02
|
BSPBio_001411
C01561
Calcidiol
Calcifediol
Calcifédiol
Calcifediol anhydrous
Calcifediol aventis brand
Calcifediol faes brand
Calcifediol organon brand
Calcifediol, (3 alpha,5Z,7E)-isomer
Calcifediol, (3 beta,5E,7E)-isomer
Calcifediolum
Calcifediolum [INN-Latin]
Calcifidiol
Calderol
CHEBI:17933
CHEMBL1040
CHEMBL1222
CID5283731
CID6433735
DB00146
Dedrogyl
Delakmin
Didrogyl
EINECS 242-990-9
Faes brand OF calcifediol
H4014_SIGMA
Hidroferol
HMS1361G13
HMS1791G13
HMS1989G13
HMS2089L21
IDI1_033881
LMST03020246
MolPort-003-927-271
Monohydrate, 25-hydroxycholecalciferol
NCGC00161326-01
NCGC00161326-04
Organon brand OF calcifediol
Rayaldee
Ro 8-8892
S1469_Selleck
Spectrum5_001931
U-32070E
UNII-T0WXW8F54E
VDY
ZINC04474414
|
|
9 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
10 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
11 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
12 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
13 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
14 |
|
Hormones |
|
Phase 4 |
|
|
|
15 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
16 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
17 |
|
Antipsychotic Agents |
|
Phase 4 |
|
|
|
18 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
19 |
|
Trace Elements |
|
Phase 4 |
|
|
|
20 |
|
Micronutrients |
|
Phase 4 |
|
|
|
21 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
22 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
23 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
24 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
25 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
26 |
|
Vitamins |
|
Phase 4 |
|
|
|
27 |
|
Nutrients |
|
Phase 4 |
|
|
|
28 |
|
Calciferol |
|
Phase 4 |
|
|
|
29 |
|
Hydroxycholecalciferols |
|
Phase 4 |
|
|
|
30 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
31 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
32 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
33 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
34 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
35 |
|
Alkylating Agents |
|
Phase 4 |
|
|
|
36 |
|
Antineoplastic Agents, Immunological |
|
Phase 4 |
|
|
|
37 |
|
Mitomycins |
|
Phase 4 |
|
|
|
38 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
39 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 4 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
40 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
41 |
|
Azelaic acid |
Approved |
Phase 3 |
|
123-99-9 |
2266 |
Synonyms:
0C50D8EC-0DB0-4F24-8EFC-2919E1F0D9BF
1,7-dicarboxyheptane
1,7-Dicarboxyheptane
1,7-Heptanedicarboxylate
1,7-Heptanedicarboxylic acid
1,9-Nonanedioate
1,9-nonanedioic acid
1,9-Nonanedioic acid
123-99-9
17265-13-3 (di-hydrochloride salt)
17356-30-8 (mono-hydrochloride salt)
19619-43-3 (unspecified potassium salt)
1tuf
246379_ALDRICH
26776-28-3
27825-99-6 (unspecified hydrochloride salt)
32733-99-6
38900-29-7 (di-lithium salt)
4-02-00-02055 (Beilstein Handbook Reference)
458317_ALDRICH
52457-54-2 (di-potassium salt)
A0561
A96150_ALDRICH
A-9800
AC1L1DAO
AC1Q75FC
acide azelaique
Acide azelaique
Acide azélaïque
Acide azelaique [French]
Acido azelaico
Ácido azelaico
Acido azelaico [Spanish]
Acidum acelaicum
acidum azelaicum
Acidum azelaicum
Acidum azelaicum [Latin]
AGN-191861
AI3-06299
AKOS000120052
Anchoate
Anchoic acid
AZ1
AZA
Azalaic acid
Azalaic Acid
Azelaate
Azelaic
azelaic acid
Azelaic acid
Azelaic acid (USAN/INN)
Azelaic acid [USAN:INN]
Azelaic acid polyanhydride
AZELAIC ACID, 95%
Azelaic acid, dilithium salt
Azelaic acid, dipotassium salt
Azelaic acid, disodium salt
Azelaic acid, monosodium salt
Azelaic acid, potassium salt
Azelaic acid, sodium salt
Azelaic acid, technical grade
Azelaic polyanhydride
Azelaicacidtech
Azelainic acid
Azelainsaeure
Azelainsäure
Azelate
Azelex
Azelex (TN)
Azleaic Acid
BIDD:GT0315
BRN 1101094
BSPBio_001756
C08261
C9H16O4
CHEBI:48131
CHEMBL1238
CID2266
D03034
DB00548
|
Dicarboxylic acid C9
DivK1c_000532
EINECS 204-669-1
Emerox 1110
Emerox 1144
Emery's L-110
Emery'S L-110
EU-0100051
Finacea
Finacea (TN)
Finevin
Heptanedicarboxylic acid
HMS1921O11
HMS2092E22
HMS501K14
HSDB 7659
I04-0585
IDI1_000532
InChI=1/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13
KBio1_000532
KBio2_000437
KBio2_003005
KBio2_005573
KBio3_001256
KBioGR_000662
KBioSS_000437
Lepargylate
Lepargylic acid
LMFA01170054
Lopac0_000051
Lopac-246379
LS-22779
MLS000069659
MLS001148615
MolPort-001-779-873
Monosodium azelate
NCGC00014993-01
NCGC00014993-02
NCGC00014993-09
NCGC00093565-01
NCGC00093565-02
NCGC00093565-03
NCGC00093565-04
NCGC00093565-05
NCGC00093565-06
NCGC00093565-07
NINDS_000532
N-Nonanedioate
n-nonanedioic acid
n-Nonanedioic acid
N-Nonanedioic acid
Nonandisaeure
Nonandisäure
Nonanedioate
Nonanedioic acid
NONANEDIOIC ACID
Nonanedioic acid azelaic acid
Nonanedioic acid homopolymer
Nonanedioic acid, homopolymer
NSC 19493
NSC19493
Poly(azelaic anhydride)
Polyazelaic anhydride
SBB060279
SDCCGMLS-0066619.P001
SH-441
Skinorem
Skinoren
SMR000059164
SPBio_001089
Spectrum_000057
SPECTRUM1500648
Spectrum2_000995
Spectrum3_000278
Spectrum4_000401
Spectrum5_001304
STL059432
UNII-F2VW3D43YT
ZK 62498
ZK-62498
|
|
42 |
|
Eliglustat |
Approved |
Phase 3 |
|
491833-29-5 |
23652731 |
Synonyms:
|
Eliglustatum
N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide
|
|
43 |
|
Mesna |
Approved, Investigational |
Phase 3 |
|
3375-50-6 |
598 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-mercaptoethanesulfonic acid
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-mercaptoethanesulphonic acid
2-Mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-sulfanylethylsulfonate
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzima M
Coenzym m
Coenzym M
Coenzyme m
CoM
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
reduced coenzyme M
Reduced coenzyme m
reduced CoM
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
β-mercaptoethanesulfonic acid
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
44 |
|
Etoposide |
Approved |
Phase 3 |
|
33419-42-0 |
36462 |
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
Eto gry
Eto-gry
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
etoposide
|
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
45 |
|
Vincristine |
Approved, Investigational |
Phase 3 |
|
2068-78-2, 57-22-7 |
5978 |
Synonyms:
(+)-Vincristine
22-Oxovincaleukoblastin
22-oxo-Vincaleukoblastine
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leucristine
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
|
Onkocristin
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
46 |
|
Doxorubicin |
Approved, Investigational |
Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
Doxo cell
Doxo-cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
|
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
47 |
|
Lenograstim |
Approved, Investigational |
Phase 3 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
48 |
|
Sargramostim |
Approved, Investigational |
Phase 3 |
|
123774-72-1, 83869-56-1 |
|
Synonyms:
123774-72-1
D05803
Leukine
Leukine (TN)
Recombinant human granulocyte-macrophage colony stimulating factor
rGM-CSF
|
rHu GM-CSF
Sargramostim
Sargramostim (genetical recombination)
Sargramostim (genetical recombination) (JAN)
Sargramostim (USAN/INN)
|
|
49 |
|
Dactinomycin |
Approved, Investigational |
Phase 3 |
|
50-76-0 |
2019 457193 |
Synonyms:
(- )-actinomycin d
(-)-actinomycin d
01815_FLUKA
1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine
2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
2-Amino-N,n'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
50-76-0
A1410_SIGMA
A4262_SIGMA
A9415_SIGMA
AC1L1CQX
AC1L9W52
Ac-de
ACon0_000471
ACon1_001004
ACT D
Actactinomycin A IV
ActD
Actinomycin
Actinomycin 11 cosmegen
Actinomycin 7
Actinomycin A IV
Actinomycin Aiv
Actinomycin C (sub1)
Actinomycin C(sub1)
Actinomycin C1
actinomycin cl
actinomycin D
Actinomycin D
ACTINOMYCIN D AMP
Actinomycin D (JP15)
Actinomycin D deriv. of 3H-phenoxaocardazine
Actinomycin D, sodium deoxyribonucleic acid complex
Actinomycin I
Actinomycin I (sub1)
Actinomycin I(sub 1)
Actinomycin I(sub1)
Actinomycin I1
Actinomycin IV
Actinomycin X 1
actinomycin x i
Actinomycin X1
Actinomycin-(threo-val-pro-sar-meval)
Actinomycin-?IV
Actinomycin-[threo-val-pro-sar-meval]
ACTINOMYCIN-D
Actinomycindioic D acid, dilactone
actinomyein-theo-val-pro-sar-meval
Acto-D
AD (VAN)
AI3-26374
Antibiotic from Streptomyces parvullus
BCBcMAP01_000155
Bio1_000342
Bio1_000831
Bio1_001320
BRD-A42383464-001-02-2
C06770
C1
C62H86N12O16
CBiol_002056
CCRIS 9
CHEBI:123721
CHEBI:27666
CHEMBL1554
CHEMBL427947
Chounghwamycin B
CID2019
CID457193
Cosmegen
|
COSMEGEN (TN)
Cosmegen lyovac
CPD000469227
D Actinomycin
D00214
Dactinomicina
Dactinomicina [INN-Spanish]
Dactinomycin
DACTINOMYCIN
Dactinomycin (USP)
Dactinomycin [USAN:BAN]
Dactinomycin D
Dactinomycine
Dactinomycine [INN-French]
Dactinomycinum
Dactinomycinum [INN-Latin]
dactinomyein d
DB00970
Dilactone actin omycindioic D acid
Dilactone actinomycin D acid
Dilactone actinomycindioic D acid
DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA
EINECS 200-063-6
FT-0080366
GNF-PF-1977
HBF 386
HBF 386 meractinomycin
HMS2052O17
HSDB 3220
Lemery brand OF dactinomycin
LMPK14000005
LS-142
Lyovac cosmegen
Lyovac, cosmegen
Lyovac-cosmegen
LyovacCosmegen
MEGxm0_000350
Meractinomycin
Merck brand OF dactinomycin
Merck frosst brand OF dactinomycin
Merck sharp and dohme brand OF dactinomycin
MLS001424196
MolPort-001-739-741
MolPort-003-925-177
MSD Brand OF dactinomycin
NCGC00025059-02
NCGC00090796-01
NCGC00161622-01
NCGC00161622-02
NCGC00169767-01
NCI60_030539
NCI-C04682
Neuro_000003
NP-005932
NSC 3053
NSC191297
NSC3053
NSC-3053
o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine
Oncostatin K
-pentone
PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA
SAM001246846
SMP1_000005
SMR000469227
UNII-1CC1JFE158
UPCMLD-DP055
UPCMLD-DP055:001
UPCMLD-DP055:002
WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1
X 97
|
|
50 |
|
Ifosfamide |
Approved |
Phase 3 |
|
3778-73-2 |
3690 |
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3,} 2-oxazaphosphorine oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC1L1GHW
AC-2113
Ambap3778-73-2
Asta Z 4942
ASTA Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
Holoxan
Holoxan 1000
HSDB 7023
I06-0494
Ifex
IFEX (TN)
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
ifosfamide
Ifosfamide
Ifosfamide (JAN/USP/INN)
Ifosfamide [USAN:INN:BAN:JAN]
|
Ifosfamide sterile
Ifosfamide Sterile
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
I-phosphamide
I-Phosphamide
Iso endoxan
Iso Endoxan
Isoendoxan
Iso-endoxan
Iso-Endoxan
Isofosfamide
Isophosphamide
isosfamide
Isosfamide
LS-102
LS-99799
Mitoxana
Mitoxana, Ifex, Ifosfamide
MJF 9325
MJF-9325
MLS002154021
MolPort-003-666-704
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
Naxamide
NCGC00016639-01
NCGC00179435-01
NCI60_000233
NCI-C01638
NPFAPI-04
NSC 109,724
NSC 109724
NSC109,724
NSC-109,724
NSC109724
NSC-109724
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z4942
Z-4942
|
|
Interventional clinical trials:
(show top 50)
(show all 108)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule |
Completed |
NCT01349829 |
Phase 4 |
|
2 |
Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial |
Completed |
NCT02760069 |
Phase 4 |
Inhaled isopropyl alcohol;Oral ondansetron;Inhaled normal saline;Oral placebo |
3 |
Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension for Sinus Endoscopic Surgery. |
Completed |
NCT03809065 |
Phase 4 |
Nitroglycerin;Labetalol |
4 |
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS |
Completed |
NCT03644212 |
Phase 4 |
Vitamin D3 |
5 |
Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck |
Terminated |
NCT02015650 |
Phase 4 |
Cetuximab;Mitomycin-C/ 5-Fluorouracil |
6 |
A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea |
Completed |
NCT01659853 |
Phase 3 |
CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15% |
7 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE) |
Completed |
NCT00891202 |
Phase 3 |
Eliglustat tartrate;Placebo |
8 |
Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma |
Completed |
NCT00354744 |
Phase 3 |
cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate |
9 |
A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea |
Completed |
NCT01355471 |
Phase 3 |
CD07805/47 Gel;Placebo |
10 |
A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea |
Completed |
NCT01355458 |
Phase 3 |
CD07805/47 gel;Placebo |
11 |
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea |
Completed |
NCT01318733 |
Phase 3 |
CD07805/47 gel 0.5% |
12 |
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea |
Completed |
NCT01789775 |
Phase 3 |
Drug: CD07805/47 gel;CD07805/47 gel Placebo |
13 |
A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months |
Completed |
NCT04074928 |
Phase 3 |
|
14 |
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer |
Completed |
NCT00171704 |
Phase 3 |
Letrozole;Tamoxifen |
15 |
Randomised, Controlled Clinical Study Regarding the Feasibility of Converting Opiate Dependents From Methadone Substitutes to Slow Release Morphine Sulphate (Sevre-Longâ„¢) |
Completed |
NCT01079117 |
Phase 3 |
Sevre-Longâ„¢;Slow release oral morphine;Methadone |
16 |
A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects |
Completed |
NCT02610868 |
Phase 3 |
MYOBLOC |
17 |
A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia |
Completed |
NCT00288509 |
Phase 3 |
|
18 |
Phase 3 Study of Vitamin D Analog (Alfacalcidol) on Muscle Strength in Elderly Indonesian Women Who Have Low Handgrip Strength |
Completed |
NCT02327091 |
Phase 3 |
alfacalcidol |
19 |
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis |
Completed |
NCT02207231 |
Phase 3 |
Guselkumab 100 mg;Placebo for guselkumab;Adalimumab;Placebo for adalimumab |
20 |
A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months |
Recruiting |
NCT03932682 |
Phase 3 |
|
21 |
Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk/ III Colorectal Cancer: Open-label Randomized Controlled |
Recruiting |
NCT02614339 |
Phase 3 |
metformin;control |
22 |
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema |
Withdrawn |
NCT01882712 |
Phase 3 |
CD07805/47 Gel 0.5%;CD07805/47 Gel Placebo |
23 |
The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark (Cinnamomum Verum and C. Aromaticum) (Cinnamonforceâ„¢) - Randomized Placebo-Controlled Clinical Trial |
Unknown status |
NCT00479973 |
Phase 2 |
|
24 |
Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea |
Completed |
NCT02300129 |
Phase 2 |
CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo;Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo;CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47;Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47 |
25 |
A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea |
Completed |
NCT01174030 |
Phase 2 |
CD07805/47 Gel;Vehicle Gel;CD07805/47 Gel;CD07805/47 Gel;Vehicle Gel |
26 |
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy |
Completed |
NCT01091974 |
Phase 2 |
armodafinil;Placebo Comparator |
27 |
A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine |
Completed |
NCT00223990 |
Phase 2 |
|
28 |
Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea |
Completed |
NCT00989014 |
Phase 2 |
CD07805/47;CD07805/47;CD07805/47;CD07805/47 placebo |
29 |
Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy. |
Completed |
NCT00596895 |
Phase 2 |
|
30 |
A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer |
Completed |
NCT00445523 |
Phase 2 |
Interferon-alpha |
31 |
Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children |
Completed |
NCT01328925 |
Phase 2 |
Nitazoxanide |
32 |
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium |
Completed |
NCT00249990 |
Phase 2 |
9-NC in aerosol reservoir |
33 |
Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome |
Completed |
NCT01029587 |
Phase 2 |
Eculizumab |
34 |
Effect of Thermal Stimulation on Cortical Excitability and Motor Function in Chronic Stroke Patients |
Completed |
NCT01407536 |
Phase 1, Phase 2 |
|
35 |
Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer |
Completed |
NCT00002774 |
Phase 2 |
Tirapazamine;Cisplatin;5-fluorouracil |
36 |
Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma |
Completed |
NCT01554059 |
Phase 2 |
Bevacizumab;Oxaliplatin;5-FU |
37 |
Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis |
Completed |
NCT00809614 |
Phase 2 |
|
38 |
Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older |
Recruiting |
NCT04563533 |
Phase 1, Phase 2 |
|
39 |
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma |
Recruiting |
NCT03047928 |
Phase 1, Phase 2 |
Nivolumab |
40 |
Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer |
Active, not recruiting |
NCT03325816 |
Phase 1, Phase 2 |
Nivolumab |
41 |
A Pilot Study of Low Dose IL-2 in the Treatment of Relapsing Polychondritis |
Not yet recruiting |
NCT04077736 |
Phase 2 |
Interleukin-2 |
42 |
Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica |
Not yet recruiting |
NCT04062006 |
Phase 2 |
Interleukin-2 |
43 |
A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001) |
Terminated |
NCT00585416 |
Phase 2 |
CGC-11047 |
44 |
IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial |
Terminated |
NCT00719914 |
Phase 2 |
eptifibatide;eptifibatide;normal saline |
45 |
A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects |
Completed |
NCT03384186 |
Phase 1 |
ACH-0144471 Modified Release Prototype 1;ACH-0144471 Modified Release Prototype 2;ACH-0144471 Modified Release Prototype 3;ACH-0144471 Modified Release Prototype 4;ACH-0144471 Modified Release Prototype 5 |
46 |
Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial. |
Completed |
NCT00292227 |
Phase 1 |
Rotigotine;Moxifloxacin infusion |
47 |
Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine. |
Completed |
NCT00317473 |
Phase 1 |
|
48 |
A 47 Hour, Single Application, Occlusive Forearm Skin Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Project Storm on the Forearm of Adult Subjects With Dry/Atopic and Very Dry/Atopic Skin |
Completed |
NCT02620293 |
Phase 1 |
|
49 |
A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIXâ„¢ in Patients With Alzheimer Disease |
Completed |
NCT00464334 |
Phase 1 |
|
50 |
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies |
Recruiting |
NCT03717103 |
Phase 1 |
IBI188;IBI188;IBI188, Rituximab |
|